INVEGA TRINZA Drug Patent Profile

When do Invega Trinza patents expire, and what generic alternatives are available?

Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-nine patent family members in twenty-seven countries.

The generic ingredient in INVEGA TRINZA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Invega Trinza

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVEGA TRINZA

International Patents:	59
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Patent Applications:	382
Drug Prices:	Drug price information for INVEGA TRINZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVEGA TRINZA
What excipients (inactive ingredients) are in INVEGA TRINZA?	INVEGA TRINZA excipients list
DailyMed Link:	INVEGA TRINZA at DailyMed

See drug prices for INVEGA TRINZA

Pharmacology for INVEGA TRINZA

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for INVEGA TRINZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	273 mg/0.875 mL and 410 mg/1.315 mL	207946	1	2021-07-14
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	819 mg/2.625 mL	207946	1	2021-04-30
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	546 mg/1.75 mL	207946	1	2020-06-24

US Patents and Regulatory Information for INVEGA TRINZA

INVEGA TRINZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-001	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-004	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-002	May 18, 2015		RX	Yes	Yes	10,143,693

Expired US Patents for INVEGA TRINZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-001	May 18, 2015	6,077,843*PED
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-003	May 18, 2015	6,077,843*PED
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-002	May 18, 2015	6,077,843*PED

International Patents for INVEGA TRINZA

When does loss-of-exclusivity occur for INVEGA TRINZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Moldova, Republic of

Morocco

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVEGA TRINZA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20170134583	장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
Mexico	2024009188	REGIMENES DE DOSIFICACION ASOCIADOS CON FORMULACIONES INYECTABLES DE PALIPERIDONA DE LIBERACION PROLONGADA. (DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMULATIONS.)
Poland	3744326

Supplementary Protection Certificates for INVEGA TRINZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0904081	11C0035	France		PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0904081	416	Finland

Market Dynamics and Financial Trajectory for INVEGA TRINZA

Last updated: February 19, 2026

What is INVEGA TRINZA?

INVEGA TRINZA (paliperidone palmitate), developed by Johnson & Johnson, is a long-acting injectable antipsychotic indicated for the treatment of schizophrenia in adults. Approved by the U.S. Food and Drug Administration (FDA) in 2015, the drug combines three monthly injections delivering sustained medication levels.

Market Size and Growth Potential

The global schizophrenia treatment market is valued at approximately USD 4.2 billion in 2022, projected to reach USD 6.1 billion by 2028, with a compound annual growth rate (CAGR) of around 6.1%.[1]

Key Drivers:

• Rising prevalence of schizophrenia globally
• Preference for long-acting injectable formulations
• Increased awareness and diagnosis rates
• Expansion into emerging markets

Competitive Landscape:

• Other long-acting injectables like RisperdalCONSTA (risperidone), Invega Sustenna (paliperidone)
• Oral antipsychotics, including risperidone and aripiprazole
• New entrants focusing on targeted delivery mechanisms

Revenue Generation and Market Adoption

Invega Trinza generated approximately USD 1.5 billion in global sales in 2022, accounting for roughly 35% of the paliperidone market segment.[2] Sales increased at a CAGR of 15% from 2018 to 2022.

Regional Breakdown:

• North America: 60%
• Europe: 25%
• Asia-Pacific: 10%
• Other regions: 5%

North America's dominance results from established healthcare infrastructure, high treatment adherence, and insurance coverage. European markets are expanding due to increased approvals and guidelines favoring long-acting injectables.

Prescribing Trends:

• Predominant in treatment-resistant schizophrenia
• Increasing use as maintenance therapy
• Preference among clinicians for quarterly injections over monthly options

Pricing and Reimbursement Landscape

The average wholesale price (AWP) for INVEGA TRINZA stands at USD 1,200 per injection.[3] Reimbursement policies vary:

• In the U.S., coverage by Medicare, Medicaid, and private insurers supports widespread adoption.
• In Europe, national health systems influence pricing and accessibility, leading to price negotiations and discounts.

Patent Status and Market Exclusivity

The original patent for paliperidone expired in 2019 in the U.S., opening opportunities for biosimilar competition. However, Johnson & Johnson maintains data exclusivity through market exclusivity and additional patents protecting formulations and delivery mechanisms until at least 2025.[4]

Pipeline and Future Revenue Streams

Potential off-label uses and new formulations are under exploration:

• Extended dosing intervals (e.g., six-month formulations)
• Combination therapies
• Digital health integration for adherence monitoring

These developments could prolong market dominance and create new revenue streams.

Challenges and Risks

• Patent expiration risks leading to biosimilar entries
• Pricing pressures amid healthcare cost containment
• Competition from oral and other injectable formulations
• Regulatory hurdles for new formulations

Financial Outlook

Johnson & Johnson projects that INVEGA TRINZA sales will grow annually at 8-10% over the next three years, driven by expanding indications, regional growth, and new formulations. The company expects the drug to account for approximately USD 2.2 billion in revenue by 2025.[5]

Key Takeaways

• INVEGA TRINZA holds a significant share in the long-acting injectable schizophrenia market.
• Sales have shown a strong growth trend, especially in North America.
• Pricing strategies and reimbursement policies greatly influence market penetration.
• Patent protection extends at least until 2025, but biosimilar competition is imminent.
• Future revenue depends on pipeline innovations and market expansion into emerging regions.

FAQs

1. What factors influence INVEGA TRINZA's market growth?
Prevalence of schizophrenia, regulatory approvals, clinician preferences, reimbursement policies, and pipeline innovations.

2. How does patent expiry impact INVEGA TRINZA?
Biosimilar competition may erode market share and pricing power post-2019 patent expiry, though exclusivity protections extend until 2025 in the U.S.

3. What are the main challenges facing INVEGA TRINZA’s market?
Biosimilar competition, pricing pressures, healthcare policy changes, and evolving treatment guidelines.

4. How does regional market variation affect sales?
North America leads sales due to established healthcare infrastructure; Europe and Asia-Pacific show growth potential, subject to regulatory and reimbursement policies.

5. What future developments could impact INVEGA TRINZA revenues?
Introduction of longer-acting formulations, digital adherence solutions, and expanded indications.

References

[1] MarketsandMarkets. (2022). Schizophrenia Treatment Market.
[2] Johnson & Johnson. (2022). Annual Report.
[3] SSR. (2022). Invega Trinza Pricing Data.
[4] U.S. Patent and Trademark Office. (2019). Patent expiration details.
[5] Johnson & Johnson. (2023). Pipeline and Revenue Forecasts.